Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (531-540 of 642) with videos related to

Pageof 65
Sort By:
JAMA|November 3, 2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudyPaul A Gurbel, David Erlinge, E Magnus Ohman, et al.
Circulation. Cardiovascular Interventions|June 1, 2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trialRobert C Welsh, Sunil V Rao, Uwe Zeymer, et al.
European Heart Journal|July 1, 2011
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyPhilippe Gabriel Steg, Kurt Huber, Felicita Andreotti, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
European Heart Journal. Acute Cardiovascular Care|March 31, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risksDiana A Gorog, Jurrien M Ten Berg, Gianluca Campo, et al.
European Heart Journal|June 22, 2019
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trialDániel Aradi, Lisa Gross, Dietmar Trenk, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 21, 2020
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trialMasafumi Ono, Mariusz Tomaniak, Wolfgang Koenig, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular PharmacologyDiana A Gorog, Jurriën M Ten Berg, Gianluca Campo, et al.
European Heart Journal. Acute Cardiovascular Care|December 17, 2013
Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countriesEtienne Puymirat, Alex Battler, John Birkhead, et al.
Journal of Clinical Medicine|April 5, 2020
Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK TrialMaria Rubini Giménez, P Elliott Miller, Carlos L Alviar, et al.
Pageof 65

Showing results (531-540 of 642) with videos related to

Sort By:
Pageof 65
JAMA|November 3, 2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudyPaul A Gurbel, David Erlinge, E Magnus Ohman, et al.
Circulation. Cardiovascular Interventions|June 1, 2012
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trialRobert C Welsh, Sunil V Rao, Uwe Zeymer, et al.
European Heart Journal|July 1, 2011
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of CardiologyPhilippe Gabriel Steg, Kurt Huber, Felicita Andreotti, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 11, 2018
Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trialEnrico Fabris, Arnoud Van't Hof, Christian W Hamm, et al.
European Heart Journal. Acute Cardiovascular Care|March 31, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risksDiana A Gorog, Jurrien M Ten Berg, Gianluca Campo, et al.
European Heart Journal|June 22, 2019
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trialDániel Aradi, Lisa Gross, Dietmar Trenk, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 21, 2020
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trialMasafumi Ono, Mariusz Tomaniak, Wolfgang Koenig, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2026
Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular PharmacologyDiana A Gorog, Jurriën M Ten Berg, Gianluca Campo, et al.
European Heart Journal. Acute Cardiovascular Care|December 17, 2013
Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countriesEtienne Puymirat, Alex Battler, John Birkhead, et al.
Journal of Clinical Medicine|April 5, 2020
Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK TrialMaria Rubini Giménez, P Elliott Miller, Carlos L Alviar, et al.
Pageof 65